Title Image

Cough spray


30mL Sprays For the treatment of Dry or Wet (productive) cough

Physiopathology: Coughing is the sudden expulsion of air from the respiratory tract (RT) to block the entry of contaminants in the lower RT & to avoid pulmonary infection. When the throat surface is damaged due to an infection (viral or bacterial), irritation or smoking, the throat mucosal cells die and produce cellular debris. Damaged mucosal surface creates a favorable ground for the growth of microorganisms leading to inflammation, liberation of cytokines, irritation, and pain & coughing as a protective mechanism.
Depending on the type of infection, the throat surface may be DRY or WET.

An Ideal treatment: To stop coughing, it is therefore essential not to block the coughing reflex but to clean the throat surface in such a way that coughing is not required. This necessitates simultaneously blocking the infection, cleaning the throat surface of all the contaminants, repairing the damaged mucosal surface, reducing inflammation, and fluidizing mucus (wet
cough) or keeping the throat surface hydrated (dry cough).

Currently available treatments: All the currently available treatments have either expectorant or mucolytics (thinning the mucus), Antitussives (centrally acting such as opioids, codeines, morphine), non-opioids (such as anticholinergic Benzonatate) acting on one of the parameters involved in coughing. These are symptomatic drugs and have multiple side-effects such as addiction, nausea, drowsiness, headache, sedation. Being target oriented and chemical in nature, their efficacy is naturally limited.

VITROBIO‘s Completely NEW therapeutic Approach:
Anti-protein hypothesis: Small dead cell debris, glycoprotein containing virus particles, pro-inflammatory cytokine are”proteins” in nature. Vitrobio concentrated its efforts (1994-2009) to identify these proteins and used specific natural polymers to block these proteins (Ref: Vitrobio new anti-viral hypothesis – Shrivastava et al: Int. J. Virology, ISSN 1816-4900 / DOI: 10.3923/ijv.2011). Neutralizing viruses, bacteria, cell debris, pro-inflammatory cytokines on the surface of the throat instantly stops new infection and allows natural defense mechanisms to get activated. When cells are healthy and in a chemical – toxin free environment, they can fight the infection and repair the damaged throat mucosal cells.
These polymers were incorporated into a glycerol-based viscous liquid, 18 times more osmotically active than sea water yet
NON-IRRITANT (VB-Gy – International patent 1997: PCT/FR99/01340). A new patent on the film retention properties of VB-Gy solution was recently filed (N° PCT/EP2013/061835). VB-GY instantly forms a film on the throat surface, creates a strong outward flow of hypotonic liquid fluidifying the dry throat surface (DRY cough) or diluting the thick & viscous mucus adhered to the throat surface (WET cough) thereby normalizing throat surface hydration. This mechanical effects equally helps detaching instantly all the microbial & other contaminants, cellular debris, polymer conjugates, thereby reducing cough reflex. The addition of a few natural, cell friendly ingredients further helps repairing the damaged throat mucosa.
Product Presentation: 30 mL Sprays for either DRY or WET cough treatments.
Posology: 4-5 sprays per application, 3-4 times a day or more if necessary, until complete recovery.
Regulatory Status: Due to the mechanical topical filmogen activity without any pharmacological, biological, metabolic or immunological interaction with the cellular structure: Class I Medical Device in Europe.
Contraindications: Not to be used in pediatric population under 8 years of age.
Side Effects: Slight tingling sensation during the first 20-30 seconds following application.
Clinical Efficacy: Full trial published in J. Clinical Trials, 2011, 1:1; DOI: 10.4172/jctr.1000102.

Conclusion: 1st topical Anti-Viral Instant Preventive or Curative
Spray to treat Viral Throat Infections